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Abstract
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Hepatocellular carcinoma (HCC), the sixth most common cancer in the world, is a global health
concern. Radiotherapy for HCC is uncommon, largely because of the likelihood of radiationinduced liver disease, an acute side effect that is often fatal. Proton beam therapy (PBT) and
intensity-modulated radiation therapy (IMRT) may offer HCC patients a better option for treating
the diseased liver tissue while largely sparing the surrounding tissues, especially the non-tumor
liver. However, even advanced radiotherapies carry a risk of late effects, including second
malignant neoplasms (SMNs). It is unclear whether PBT or IMRT confers less risk of an SMN
than the other. The purpose of this study was to compare the predicted risk of developing an SMN
for a patient with HCC between PBT and IMRT. For both treatments, radiation doses in organs
and tissues from primary radiation were determined using a treatment planning system; doses in
organs and tissues from stray radiation from PBT were determined using Monte Carlo simulations
and from IMRT using thermoluminescent dosimeter measurements. Risk models of SMN
incidence were taken from the literature. The predicted absolute lifetime attributable risks of SMN
incidence were 11.4% after PBT and 19.2% after IMRT. The results of this study suggest that
using proton beams instead of photon beams for radiotherapy may reduce the risk of SMN
incidence for some HCC patients.
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1. Introduction
Worldwide, liver cancer is the sixth most common cancer and ranks third as the cause of
cancer-related deaths, with an estimated 711 000 new cases diagnosed and approximately
680 000 cancer-related deaths in 2007. Liver cancer mainly occurs in China and other
developing countries (Garcia et al 2007). It is less common in the United States than
elsewhere: in 2009, US incidence was predicted at 22 620 cases and mortality at 18 160
(Horner et al 2008). Hepatocellular carcinoma (HCC) accounts for 70–85% of liver cancer
cases worldwide (Perz et al 2006). Within the US, the incidence of HCC per hundred
thousand people has tripled between 1975 and 2005, from 1.6 cases to 4.9, largely because
of a rapid increase in the number of people infected with the hepatitis C virus. Although the
one-year survival rate of US patients with HCC has improved in the last decade, it is still
below 50%, and there is considerable room for improvement (Altekruse et al 2009).
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Relative to other alternatives to surgery, radiotherapy historically has not been widely
employed as a treatment option for HCC, largely because of the perceived risk of radiationinduced liver disease (RILD). RILD is an acute effect that occurs within 6 months of
irradiation, and it is commonly lethal within a few months of diagnosis. With recent
improvements in modeling the risk of RILD and in radiation planning and delivery
techniques (such as the use of conformal, image-guided, respiratory-gated and chargedparticle therapies), it appears increasingly probable that curative doses of radiation can be
administered to partial liver volumes while sparing the portion of the liver not involved by
tumor (hereafter referred to as ‘non-tumor liver’) (Krishnan et al 2008). This option is
particularly appealing as a bridge to transplantation in patients awaiting a donor liver.
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In addition to RILD, survivors of HCC who undergo radiotherapy are at risk of radiation
carcinogenesis, which is the late effect of greatest concern for radiotherapy patients with
good prognoses for long-term survival. Minimizing the radiation dose to normal tissues
throughout the body is important in avoiding second malignant neoplasms (SMNs). Normal
tissue exposures may be minimized using intensity-modulated radiation therapy (IMRT) or
proton beam therapy (PBT) (Zurlo et al 2000, Krishnan et al 2008, Dawson 2009). Both
IMRT and PBT deliver the conformal dose to the clinical target volume (CTV), but
comparative SMN risk assessment is challenging (cf Newhauser et al 2009), requiring
knowledge of therapeutic, scatter and leakage radiation doses. Taddei et al (2009a) predicted
the equivalent dose from stray radiation throughout the body of a patient receiving PBT for
HCC using Monte Carlo simulations of the treatment; the doses from the primary proton
fields were not reported. Howell et al (2010) described a methodology for quantifying the
radiation dose from both primary and stray radiation in photon radiotherapy treatments,
including IMRT. They applied this methodology to the same patient studied in this work,
quantifying the absorbed dose from both primary and stray (i.e. scatter and leakage)
radiation associated with IMRT. However, no previous reports directly compared the
predicted risks for developing radiogenic SMNs following IMRT and PBT.
The aims of this study were to predict and compare the risks of SMN incidence after IMRT
and PBT for a patient with primary HCC. Organ and tissue doses were determined
throughout the body from primary and stray radiation. Based on these organ doses and risk
models from the literature, we predicted the organ-specific risks of SMN incidence.

2. Methods and materials
2.1. Treatment planning
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Two treatment plans were designed separately for a patient diagnosed with HCC at our
clinic, one for PBT and one for IMRT, each according to the standard of care of our
institution. The intent of the treatment was to cure the primary lesion. The patient was a 59year-old male, with a height of 174 cm and a mass of 93.9 kg; he was randomly selected
among HCC patients. Our study was performed under a protocol approved by our
institutional review board for retrospective treatment planning studies. The treatment plans
were based on the standard of care at our institution for PBT and IMRT treatments of liver
cancer. Free-breathing kilovoltage computed tomography (CT) images were acquired for
treatment planning purposes; the images extended from the patient’s mid-thigh to the top of
the head, and the slice thickness was 5 mm. Organ and tissue structures were contoured and
PBT and IMRT plans were created using a commercial TPS (Eclipse; Varian Medical
Systems, Inc., Palo Alto, CA) and the free-breathing CT image set (Newhauser et al 2007a).
The following tumor volumes were contoured: the gross tumor volume, the CTV (i.e. the
gross tumor volume plus subclinical disease) and the planning target volume (PTV) (i.e.
CTV plus internal and setup margins for the IMRT plan).
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The IMRT plan was optimized for nine 6-MV photon fields so that 95% of the prescribed
dose of 60 Gy would be delivered to 100% of the PTV. The IMRT fields were shaped
laterally with dynamic multi-leaf collimator settings, four of which were coplanar and five
were non-coplanar. The normal tissue objectives included constraints of less than 28 Gy
mean dose to the non-tumor liver, less than 40% of the non-tumor liver receiving 30 Gy, less
than 50% of the right (ipsilateral) kidney receiving 20 Gy and less than 30% of the left
(contralateral) kidney receiving 20 Gy. Details of the IMRT plan are reported in a
companion article (Howell et al 2010).
The PBT plan comprised two proton fields to deliver a prescribed dose of 60 Gy to 100% of
the CTV. To facilitate a direct comparison with the IMRT plan, the PBT plan was renormalized so that 95% of the PTV received 60 Gy as was the case for the IMRT plan. The
two fields were in the posterior oblique orientation, with gantry angles of 220° and 135°,
couch angles of 45° and −40°, penetration ranges in the patient of 20.1 cm water equivalent
thickness (WET) and 25.0 cm WET and spread-out Bragg peak widths of 14 cm WET and
13 cm WET for field 1 (PO1) and field 2 (PO2), respectively. Beam shaping devices for the
PBT treatment unit included a range modulator wheel, scattering foil, range shifter, fielddefining collimator and range compensator; the latter two components accommodated
collimated fields up to 18 × 18 cm2 in size. Details of the PBT treatment plan were reported
previously (Taddei et al 2009a).
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For predicting risk of SMN incidence, we also contoured the whole liver, non-tumor liver,
kidneys, stomach, colon, lungs, prostate, bladder, thyroid, red bone marrow, non-tumor body
tissue and several other structures. The following two sections describe the equipment and
methods used for determining the doses to these organs and tissues.
2.2. Determining organ doses for PBT
For PBT, the absorbed doses from primary radiation were calculated using the TPS, and the
stray radiation doses were determined using a Monte Carlo system. Absorbed dose from the
primary proton field in each voxel, Dv(pri, PBT), was calculated in 2 × 2 × 2.5 mm3 voxels
throughout the patient’s body. DT(pri, PBT) was the mass-weighted average absorbed dose
for all voxels within a particular organ, T, or

(1)
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where ρv is the mass density of the tissue within a voxel. The equivalent dose, HT, was the
product of the mean radiation weighting factor, , and DT, or
(2)

where
was taken as 1 for primary proton fields, as suggested by the National Council on
Radiation Protection and Measurements (NCRP 1993) for incident protons with energy
greater than 100 MeV.
To determine the doses from stray radiation, we used the Monte Carlo Proton Radiotherapy
Treatment Planning (MCPRTP) system (Newhauser et al 2007a, 2008b), which uses the
Monte Carlo N-Particle eXtended (MCNPX) code version 2.6b (Pelowitz 2008). In PBT,
secondary neutrons are the chief source of the equivalent dose from stray radiation (Agosteo
et al 1998, Fontenot et al 2008, Zheng et al 2008). Neutrons are produced both in the patient
Phys Med Biol. Author manuscript; available in PMC 2010 December 13.
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(analogous to patient scatter in photon radiotherapy) and in the treatment unit (analogous to
leakage and collimator scatter in photon radiotherapy). The geometric model in the Monte
Carlo simulations included all components of the treatment unit and detailed CT-based
voxelized phantom representing the patient, in which the Hounsfield unit value for each 4 ×
4 × 5 mm3 voxel was converted to a mass density and a material composition (Newhauser et
al 2007b, 2008a, Taddei et al 2009b). In the MCPRTP system, Dv was calculated for
neutrons produced in the treatment unit (external neutrons), Dv(next), and for neutrons
produced in the patient (internal neutrons), Dv(nint), in separate simulations for each
treatment field. The corresponding mean absorbed doses, DT(next) and DT(nint), were
calculated using equation (1) and the HT values were calculated using equation (2). The
values for external neutrons were determined for each treatment field based on the Monte
Carlo simulations of the neutron spectral fluence incident upon the patient, following the
recommendations of the International Commission on Radiological Protection (ICRP)
Publication 92 (2003). The
values for internal neutrons were estimated based on the
calculations of Zheng et al (2008). Finally, for each treatment field, the equivalent dose from
stray neutron radiation, HT(str, PBT), was the sum of the external and internal neutron
contributions, or
(3)
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These values were normalized following the methods reported by Taddei et al (2009c).
Details of the methods of determining HT(str, PBT) were published previously (Taddei et al
2009a). They reported
values for external neutrons of 8.89 and 8.94 for fields PO1 and
PO2, respectively, and
values for internal neutrons at 9.6 for each field.
2.3. Determining organ doses for IMRT
For IMRT, dose volume histogram (DVH) data were exported from the TPS and used to
determine the absorbed dose from primary radiation to in-field organs. Thermoluminescent
dosimeter (TLD) measurements were made in an anthropomorphic phantom to determine
absorbed dose values from stray radiation for out-of-field organs. Either calculated doses or
a combination of calculated and measured doses were used to determine absorbed dose for
partially in-field organs. The methods to determine the organ doses for the IMRT plan were
described, and the organ dose results were reported elsewhere (Howell et al 2010) and are
briefly summarized below.
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For in-field organs, the mean organ absorbed dose values from primary radiation were taken
directly from the TPS. Absorbed dose was calculated in 2 × 2 × 2.5 mm3 voxels throughout
the patient’s body, and the mean organ absorbed dose from primary protons, DT (pri,
IMRT), was determined using equation (1). For completely out-of-field organs, the mean
organ absorbed dose values from stray radiation were determined from measurements made
within an adult-sized male anthropomorphic phantom, with CT images of the phantom
registered to those of the patients in the TPS and the treatment isocenters for the patient and
the phantom anatomically registered. The phantom was irradiated using the patient’s
treatment plan, and the absorbed dose was measured using lithium fluoride TLDs at
locations corresponding to the organs of interest. The mean organ absorbed dose from stray
radiation, DT (str, IMRT), was calculated as an average of all TLD measurements within an
organ and was normalized per therapeutic absorbed dose delivered to isocenter. For partially
in-field organs, a sensitivity analysis was performed to determine if the DVH data were
sufficiently accurate for calculating the mean organ dose. If the sensitivity analysis found
that the accuracy of the out-of-field component of dose had a significant effect on the mean
organ absorbed dose, DT (pri+str, IMRT) was calculated based on a volume-weighted

Phys Med Biol. Author manuscript; available in PMC 2010 December 13.

Taddei et al.

Page 5

technique, which combined the TPS estimate of the in-field component of dose with a
measured out-of-field component of dose.
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The HT value for each type of photon radiation was calculated using equation (2), with
1, following the recommendations of ICRP Publication 92.

of

2.4. Risk of SMN incidence
Lifetime absolute risk of SMN incidence, IT, attributable to radiation exposures in PBT and
IMRT treatments, was estimated according to

(4)

where the risk coefficients IT/HT (table 1) were taken directly from the age-, sex- and organspecific risk model in table 12D-1 of the BEIR VII Report (NRC 2006). This model from
the BEIR VII Report assumes a risk-free latent period of 2 years for leukemia and 5 years
for all other cancers. The HT values were determined according to sections 2.2 and 2.3 of
this work. The risk coefficient for liver cancer was only applied to the HT value for nontumor liver.
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2.5. Risk of non-melanoma skin cancer incidence
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To calculate the organ dose in skin for IMRT, Dskin(IMRT), and to predict the risk of nonmelanoma skin cancer (NMSC) incidence after IMRT and PBT, the methods described in
sections 2.2–2.4 were slightly modified. The values for Dskin(IMRT) were estimated by
taking a volume-weighted average of the in-field dose (8% of the skin volume) and out-offield dose (92% of skin volume). The out-of-field component of Dskin(IMRT) was not
measured in the previous study by Howell et al (2010). Therefore, for the out-of-field
component of Dskin(IMRT), we used data from a previous study by Howell et al (2006) for a
6 MV IMRT treatment, in terms of Dskin(IMRT) per monitor unit (MU), and the number of
MUs delivered in the liver study by Howell et al (2010). More specifically, we multiplied
the out-of-field Dskin(IMRT)/MU from Howell et al (2006) of 3.75 × 10−6 Gy MU−1 by the
total MUs required to deliver the 60 Gy prescription dose from Howell et al (2010) of 38
720 MU to obtain Dskin(IMRT). Dskin(PBT), Hskin(IMRT) and Hskin(PBT) were determined
with the same methods as the other organs. Because a recommendation for the risk
coefficient for NMSC, Iskin/Hskin, was not provided in the BEIR VII Report, we applied the
risk coefficient recommended by the ICRP in Publication 60 (ICRP 1991). To correct for
age at exposure, we multiplied Iskin/Hskin by an age-correction factor of 0.45. The final value
of Iskin/Hskin is listed in table 1.

3. Results
3.1. Organ doses
Table 2 lists the mean equivalent doses in organs and tissues from primary and stray
radiation for PBT and IMRT. For organs that were in or near the primary field, the primary
field dominated the mean organ dose. For organs that were far away from the primary field,
however, the stray radiation dominated the mean organ dose. Figure 1 plots DVHs for
primary radiation. Figure 2 shows the distributions of Dv in the axial, sagittal and coronal
planes through isocenter from primary radiation of PBT and IMRT. The superior normal
tissue sparing of primary radiation doses from PBT relative to IMRT is evident in these
figures, particularly for the esophagus, stomach, left kidney and non-tumor liver. In the
IMRT plan, 63% of the non-tumor liver received at least 10 Gy, while only 29% of the nonPhys Med Biol. Author manuscript; available in PMC 2010 December 13.
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tumor liver received at least 10 Gy in the PBT plan. However, the DVHs for the non-tumor
liver were similar above 30 Gy, with the PBT plan having slightly more non-tumor liver in
the high-dose region. Importantly, the mean dose in the non-tumor liver was less with PBT.
Because the absorbed dose values from primary radiation for PBT and IMRT were based on
the absorbed doses calculated by the TPS, the uncertainties in these values were assumed to
be less than 3% in-field. The statistical uncertainties in the mean equivalent dose in each
organ or tissue from stray radiation for PBT were less than 3% for the Monte Carlo
calculations and were reported at the 68% confidence interval. The measurement uncertainty
was less than 3% for each TLD measurement, so the mean equivalent dose from stray
radiation for IMRT was less than 3% for each organ or tissue. Together, the uncertainties in
the primary and stray radiation mean equivalent dose values in each organ or tissue were
less than 3% for PBT and IMRT.
3.2. Risk of SMN incidence
Figure 3 plots the predicted lifetime risks of SMN incidence by cancer site after PBT and
IMRT. For each treatment, the risks take into account both primary and stray radiation. The
total risks of SMN incidence, summed over all cancer sites, were 11.4% and 19.2% after
PBT and IMRT, respectively. For PBT, approximately one-fourth of the predicted risk was
from stray radiation.
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4. Discussion
In this comparison of the predicted risk of SMN incidence after PBT or IMRT for a 59-yearold male patient with HCC, we found that PBT reduced the risk by approximately 40%
relative to IMRT (from 19.2 to 11.4% lifetime risk). Additionally, we found that PBT spared
the non-tumor liver and other normal tissues more than IMRT, which may lead to reduced
incidences of RILD, other toxicities and other normal tissue complications. Reducing dose
to the non-tumor liver also introduces the possibility of escalating dose to the target volume.
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Liver cancer is a deadly disease, and novel and improved radiation treatment strategies are
urgently needed to reduce normal tissue toxicities. Our data revealed that using PBT almost
halved the predicted risk of SMN incidence in a long-term survivor of liver cancer.
Reducing SMN risk is becoming more important as the long-term prognosis improves for
liver cancer patients who are candidates for radiotherapy. For example, in HCC patients who
received PBT as a bridge to liver transplantation, 5-year survival rates have reached 70%
(Llovet 2005). In fact, in a group of HCC patients who had solitary tumors and minimal
impairment of hepatic function due to cirrhosis, the reported 5-year survival rate achieved
by PBT was greater than 50%, rivaling the outcomes reported for similar cases following
surgical resection (Chiba et al 2005). These promising results suggest that radiotherapy can
be employed with curative intent in the treatment of HCC.
While the therapeutic fields dominated the risk after both PBT and IMRT, the risk from
stray radiation was substantial, and reasonable measures should be taken to reduce the
normal tissue doses from stray radiation in PBT (Taddei et al 2008, 2009d, Brenner et al
2009) and in IMRT (Kry et al 2010, Chofor et al 2010). Quantifying and reducing stray
radiation exposure appear to be manageable tasks in developing PBT and IMRT treatments
for liver cancer.
Sparing the non-tumor liver from radiation dose is of particular importance for reducing the
probability of RILD, which is often fatal; patients with underlying cirrhosis and hepatic
dysfunction are at particularly high risk of death due to RILD. The mean equivalent dose in
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the non-tumor liver was 29% less for PBT than for IMRT, which suggests the possibility of
reducing the risk of RILD.

NIH-PA Author Manuscript

Our findings are in good agreement with previous dosimetric studies. Wang et al (2008)
performed a dosimetric comparison between photon radiotherapy and proton beam
radiotherapy for nine patients with intrahepatic malignancies. From their TPS-based
dosimetric comparisons, they concluded that protons were superior to photons in
conforming the dose to the target and reducing dose to critical structures. However, they
neglected stray radiation, which is especially important outside the treatment volume.
One limitation of our study was that it was theoretical. That is, we predicted radiation
exposures and risks for a single patient rather than following up a cohort of patients for
many years. We relied on risk models from the literature that were derived from data from a
general population, mainly atomic bomb survivors, and the application of these risk models
to a cancer patient introduced uncertainty in the risk predictions that is difficult to quantify
(NRC 2006,Fontenot et al 2009,Newhauser et al 2009). Confirmatory patient follow-up
studies are needed but may take a decade or more due to the latency time of some SMNs.
In summary, the findings of this study suggest that using PBT rather than IMRT reduced the
predicted lifetime risk of SMN incidence in a patient with HCC.
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Figure 1.

DVHs from the primary fields for in-field or partially in-field structures, normalized so that
95% of the PTV receives the prescribed dose of 60 Gy. DVHs for the CTV, PTV of the
IMRT plan, right kidney, esophagus, non-tumor liver, stomach, left kidney and lungs are
shown for the PBT (triangles) and IMRT (squares) plans.
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Figure 2.

Predicted dose distributions from the primary fields for IMRT (left) and PBT (right) in the
axial (top), coronal (lower left) and sagittal (lower right) planes through isocenter. The
contour marked in purple is for the CTV.
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Figure 3.

Site-specific predicted lifetime risks of SMN incidence after PBT and IMRT. Other solid
SMN risks are based on the mean dose in the non-tumor body tissue. Leukemia risks are
based on the mean dose in the red bone marrow.
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Risk coefficients for SMN incidence, IT/HT, for 60-year-old males from table 12D-1 in the BEIR VII report
(NRC 2006), except for Iskin/Hskin, which was from ICRP Publication 60 (ICRP 1991), listed in terms of
absolute risk (in percent) per equivalent dose.
Cancer site

IT/HT (%/Sv)

Stomach

0.20

Colon

0.94

Liver

0.14

Lung

0.89

Prostate

0.26

Bladder

0.66

Other

0.98

Thyroid

0.003

Leukemia

0.82

Skin

2.2
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Table 2
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Mean organ equivalent dose PBT, including primary proton radiation, stray (external and internal) neutron
radiation (from Taddei et al (2009a)) and a sum of both primary and stray radiation. For IMRT, the combined
dose from both primary and stray radiation (from Howell et al (2010) and Howell et al (2006)) is listed. The
statistical uncertainty of each value is less than 3%.
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PBT
primary (Sv)

PBT
stray (Sv)

PBT
total (Sv)

IMRT
total (Sv)

CTV

66.11

1.89

68.00

63.99

PTV

65.29

1.82

67.11

63.52

Whole liver

23.64

1.03

24.67

28.62

Non-tumor liver

13.61

0.84

14.45

20.40

Right kidney

25.66

1.36

27.02

27.00

Left kidney

0.00

0.38

0.38

3.59

Stomach

0.01

0.45

0.46

10.20

Colon

0.05

0.33

0.38

1.89

Lungs

2.97

0.57

3.54

3.14

Prostate

0.00

0.16

0.16

0.13

Bladder

0.00

0.16

0.16

0.32

Thyroid

0.00

0.26

0.26

0.46

Red bone marrow

1.34

0.39

1.73

2.31

Skin

0.77

0.36

1.13

1.06

Esophagus

0.74

0.61

1.35

11.20

Whole body

1.85

0.36

2.21

6.17

Non-tumor body tissue

1.41

0.36

1.77

5.31

Organ or tissue
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